Julphar Bangladesh Ltd., a subsidiary of Julphar, UAE, started its journey on July 31, 2009. The visionary leader, His Highness the ruler of Ras Al Khaimah (RAK), Sheikh Saud Bin Saqr Al Qusimi the architect of the global conglomerate RAK Group, initiated the journey of Julphar Bangladesh Ltd.
The state of the art manufacturing facilities with an area of 228,705 sq ft is located 42 kilometers north of Dhaka under Sreepur Upazilla of Gazipur District. The facilities have the strength of general manufacturing unit, dedicated Cephalosporin unit, advanced three layer floors, prototype R & D laboratories, Effluent Treatment Plant (ETP) & advanced water treatment system with recycling facilities. Presently Julphar Bangladesh Ltd. has more than 100 products including Antibiotics/ Antimicrobials, Anti-ulcerants, Anti-inflammatory, Anti-hypertensive, Oral Anti-diabetics, Dermatological and Nutritional supplements. Read More..
Press Releases & Events
Julphar Bangladesh is passionate to introduce new and better molecules, strengths & dosage forms of various therapies in the market. Another feather of this effort is Roxibac Plus (Cefuroxime & Clavulanic acid) the most trusted antibiotic combination as Roxibac Plus 250 & Roxibac Plus 500 tablet.Cefuroxime, a broad spectrum second generation Cephalosporin has excellent... Read More
On March 15th, 2017 Julphar Bangladesh- Intensiva Division organized a CME program at Shaheed Suhrawardy Medical College & Hospital on Infections control in ICU with an audience of 43 Doctors. The event, which took place in Dhaka, was part of the company’s commitment to support and provide healthcare professionals (HCPs) and patients with high quality and affordable... Read More
Julphar Bangladesh relentlessly thriving not only with new molecules but also with newer strength. As a continuation on 8th March, 2017 Julphar Bangladesh has launched Doxair 200 (Doxophylline 200 mg), a novophylline ensuring easy breathing.
Doxophylline, a new generation xanthine derivative with a dioxalane group at N-7 position of its chemical structure shows less affinity... Read More
Julphar Bangladesh has celebrated Maxwel launching program in 155 major institutes of the country.
These programs have been arranged mainly in Medicine and Gynae units of Medical College Hospitals, Sadar Hospitals, Specialized Hospitals and Thana Health Complexes.
In the programs we have inaugurated Maxwel through cake-cutting by the doctors with product... Read More
Through relentless efforts and our devotion to introduce the latest molecules in Bangladesh, Julphar Bangladesh introduced Eltrom (Eltrombopag 25 mg) tablet to treat patients with thrombocytopenia.
Eltrombopag was initially approved by the U.S. Food and Drug Administration on November 20, 2008, for the treatment of thrombocytopenia in patients with chronic immune (idiopathic)... Read More
Julphar Bangladesh has introduced another new product Maxwel, for maximum well-being, a complete multivitamin & multimineral supplement with accurate balance of RDA. In many instances regular diet isn’t enough to meet the requirements of all key health benefits like energy, immunity, metabolism, blood, heart function, bones health, eyesight & well health. To ensure... Read More
Julphar Bangladesh has celebrated Refla 24 mg launching program in 168 major institutes of the country.We have arranged these programs in Orthopedics, ENT & Medicine, and Respiratory units of Medical College Hospitals, Sadar Hospitals, Specialized Hospitals and Thana Health Complexes.
In the programs we have inaugurated Refla 24 through cake-cutting by the... Read More
Considering the safety profile, in July 2015 Julphar Bangladesh launched Refla, a safer anti-inflammatory steroid, preparation of Deflazacort 6 mg tablet. In acute inflammatory and allergic disorders recommended initial dose of Deflazacort is up to 120 mg daily. In acute bronchial asthma recommended daily dose of Deflazacort is 48-72 mg.
For safety & treatment compliance in acute disorders,... Read More
Through relentless effort and our devotion to introduce the latest molecules in Bangladesh for the treatment of Hepatitis C, first time in Bangladesh, Julphar Bangladesh introduced blockbuster product Velpacee (Velpatasvir 100 mg & Sofosbuvir 400 mg) tablet. We have introduced the product with the API of FDA approved source.
Velpatasvir/Sofosbuvir (trade name Epclusa) is a two drug... Read More
After successful introduction of Hepatitis C product in our virology portfolio from 2015, we are the consistent leader in this Hepatitis C market. Now, Julphar Bangladesh has launched another new class of drug of targeted therapy the name is Nexanib 200 (Sorafenib 200 mg) tablet for the treatment of Hepatocellular Carcinoma (HCC).
Targeted therapy... Read More
Julphar Bangladesh has launched another breakthrough Molecule Butamirate Citrate (Butasiv 50 mg Tablet & 100 ml Syrup) for Better management of cough.
Solution for all types of cough
Suppresses cough centre
Expectorates sputum by relaxing bronchial muscle
Provides extra benefits as anti-inflammatory & bronchodilatory action
Relives cough within 30... Read More
After successful introduction of Hepatitis C product in our virology portfolio from 2015, we are the consistent leader in this Hepatitis C market. Now, Julphar Bangladesh has launched antiviral drug Enbee 0.5 (Entecavir 0.5 mg) tablet for the treatment of Hepatitis B viral infection.
Stay ahead of CHB
AASLD, APASL & WHO recommended Enbee as first line therapy... Read More
Julphar Bangladesh, subsidiary of the Ras Al Khaimah-based generic pharmaceutical company Julphar Gulf Pharmaceutical Industries, is pleased to announce the strategic toll agreement with the Bangladeshi nonprofit private limited company SMC Enterprise Limited (SMC-EL) to manufacture pharmaceutical products. The agreement was signed at the SMC head office in Dhaka, Bangladesh on May 4th... Read More
Julphar Bangladesh has launched Super Antioxidant Greenox- (Astaxanthin 4mg Capsule)
Live Green with Super Antioxidant
800 times stronger than CoQ10
6000 times stronger than Vitamin C
550 times stronger than Vitamin E
Superior cell protector
Most stable antioxidant
Provides neuro & eye protection
Improves cholesterol balance & blood vessel health
Reduces... Read More
Julphar Bangladesh has launched another breakthrough Molecule Doxair (Doxophylline 400 mg Tablet) for Better management of Asthma & COPD
Provides both Bronchodilatory and Anti-inflammatory effect
Shows outstanding efficacy in Asthma & COPD
Ensures Cardiac safety
Ensures normal sleep
Ensures Renal & GI safety
DMF grade best quality API
1 tablet once... Read More
To extend the horizon of Antiviral treatment Julphar Bangladesh has launched another breakthrough Antiviral product Daclacee (Daclatavir 60 mg) first time in Bangladesh.
Provide Pangenotypic anti-HCV activity
High SVR rate
Less treatment duration and cost
Convenient oral treatment regimen
Daclacee (Daclatasvir 60 mg) tablet can be taken orally once daily with Hepcee (Sofosbuvir 400 mg),... Read More
Julphar Bangladesh Ltd. (previous RAK pharmaceuticals Pvt. Ltd.) has partnered with global pharmaceutical leader Hetero drugs, with the vision of diversifying its growth to better serve our communities, in need of fighting back diseases to restore healthy and productive life. As a part of relentless efforts to meet the unmet need of the patients & considering the safety... Read More
GCC countries import medicines mainly from USA, UK & highly regulated countries. Their strict adherence to the medicines from the western world, stringent evaluation process of manufacturing facilities, practice, procedures and documentation to ascertain the implementation of rigorous legislations of Ministry of Health, made it almost impossible for the pharmaceutical companies in the... Read More
It is our great pleasure to inform that we have launched Palorex 0.5 mg tablet preparation of Palonosetron HCL, a latest antiemetic, which is long-acting and highly effective in -5HT3 receptor antagonist. Palorex controls nausea and vomiting with safety because it has no congenital and cardio-toxicity.
It is our great pleasure to inform that we are going to launch Rinobas 10 mg tablet preparation of Ebastine, a latest novel antihistamine, which is long-acting and highly selective H1-histamine receptor antagonist. Rinobas controls allergic conditions with safety because it has no CNS and cardio-toxicity.